- Home
- DGII vs SNDX Comparison
DGII vs SNDX Comparison
Compare DGII & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGII
- SNDX
- Stock Information
- Founded
- DGII 1985
- SNDX 2005
- Country
- DGII United States
- SNDX United States
- Employees
- DGII N/A
- SNDX N/A
- Industry
- DGII Computer peripheral equipment
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- DGII Technology
- SNDX Health Care
- Exchange
- DGII Nasdaq
- SNDX Nasdaq
- Market Cap
- DGII 1.3B
- SNDX 1.1B
- IPO Year
- DGII N/A
- SNDX 2016
- Fundamental
- Price
- DGII $36.30
- SNDX $14.75
- Analyst Decision
- DGII Buy
- SNDX Strong Buy
- Analyst Count
- DGII 4
- SNDX 10
- Target Price
- DGII $38.75
- SNDX $38.40
- AVG Volume (30 Days)
- DGII 195.0K
- SNDX 2.0M
- Earning Date
- DGII 11-12-2025
- SNDX 11-04-2025
- Dividend Yield
- DGII N/A
- SNDX N/A
- EPS Growth
- DGII 147.46
- SNDX N/A
- EPS
- DGII 1.14
- SNDX N/A
- Revenue
- DGII $420,935,000.00
- SNDX $77,933,000.00
- Revenue This Year
- DGII $2.46
- SNDX $585.73
- Revenue Next Year
- DGII $7.77
- SNDX $94.17
- P/E Ratio
- DGII $32.01
- SNDX N/A
- Revenue Growth
- DGII N/A
- SNDX 2126.66
- 52 Week Low
- DGII $22.39
- SNDX $8.58
- 52 Week High
- DGII $37.07
- SNDX $22.50
- Technical
- Relative Strength Index (RSI)
- DGII 61.38
- SNDX 47.48
- Support Level
- DGII $35.01
- SNDX $15.71
- Resistance Level
- DGII $36.94
- SNDX $16.50
- Average True Range (ATR)
- DGII 1.08
- SNDX 0.81
- MACD
- DGII 0.18
- SNDX -0.36
- Stochastic Oscillator
- DGII 81.87
- SNDX 2.73
About DGII Digi International Inc.
Digi International Inc is a Minnesota corporation. The company provides business and mission-critical and Internet of Things (IoT) connectivity products and services. It has two segments: IoT Products and Services and IoT Solutions. The IoT Products and Services segment consists of distinct communications products and communication product development services. IoT Solutions segment offers wireless temperature and other environmental condition monitoring services as well as employee task management services. The company generates majority of its revenue from the IoT Products & Services segment. Geographically, the company generates majority of its revenue from its business in the United States and also has its presence in Europe, Middle East and Africa and Rest of the world.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.